Document is current
Any future updates will be listed below
-
Authors
Wu, Xiaoai https://orcid.org/0000-0002-3518-9689
Xiang, Yongzhao
Zalutsky, Michael R.
Liu, Ning
Li, Xin
Du, Yong
Feng, Yutian
Li, Feize https://orcid.org/0000-0001-9255-3048
Tian, Rong https://orcid.org/0000-0002-5191-9004
-
Funding
Funding for this research was provided by:
The State Administration of Science Technology and Industry for National Defense (HNKFHBZ202322)
National Natural Science Foundation of China (12475349)
Sichuan Province Science and Technology Support Program (2023NSFSC1714)
National Institutes of Health (CA184228)
- License Information
-
More Information
Article History
Received: 13 October 2025
Accepted: 29 December 2025
First Online: 10 February 2026
Declarations
:
: All animal experiments were approved and performed following the guidelines of the Duke University Institutional Animal Care and Use Committee (IACUC). Human investigation was approved by the West China Hospital Ethics Committee.
: The authors have consent to publish all the data in the manuscript.
: Michael Zalutsky is a shareholder in Z-Alpha Therapeutics. and is entitled to royalty distributions from Z-Alpha related to the [ 211 At]YF2 agent described herein. No other potential conflicts of interest relevant to this article exist.
